围手术期ONS联合肠道微生态制剂对结直肠癌患者术后的影响

注册号:

Registration number:

ChiCTR2600126613 

最近更新日期:

Date of Last Refreshed on:

2026-06-12 10:23:47 

注册时间:

Date of Registration:

2026-06-12 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

围手术期ONS联合肠道微生态制剂对结直肠癌患者术后的影响

Public title:

Effects of Perioperative Oral Nutritional Supplements Combined with Intestinal Microecological Agents on Patients Undergoing Colorectal Cancer Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围手术期ONS联合肠道微生态制剂对结直肠癌患者术后的影响

Scientific title:

Effects of Perioperative Oral Nutritional Supplements Combined with Intestinal Microecological Agents on Patients Undergoing Colorectal Cancer Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘轩君 

研究负责人:

李启刚 

Applicant:

Liu Xuanjun 

Study leader:

Qigang Li 

申请注册联系人电话:

Applicant telephone:

+86 13350273603

研究负责人电话:

Study leader's
telephone:

+86 23 85381638

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1249493851@qq.com

研究负责人电子邮件:

Study leader's E-mail:

ycliqigang@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市永川区萱花路439

研究负责人通讯地址:

重庆市永川区萱花路439

Applicant address:

No. 439 Xuanhua Road, Yongchuan District, Chongqing, China

Study leader's address:

No. 439 Xuanhua Road, Yongchuan District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属永川医院

Applicant's institution:

Yongchuan Hospital Of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属永川医院

Affiliation of the Leader:

Yongchuan Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023LLS040

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属永川医院临床研究伦理审查委员会

Name of the ethic committee:

Clinical Research Ethics Committee ,Yongchuan Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-29 00:00:00

伦理委员会联系人:

唐宇

Contact Name of the ethic committee:

Tang Yu

伦理委员会联系地址:

重庆市永川区萱花路439

Contact Address of the ethic committee:

No. 439 Xuanhua Road, Yongchuan District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 85381616

伦理委员会联系人邮箱:

Contact email of the ethic committee:

2992107908@qq.com

研究实施负责(组长)单位:

重庆医科大学附属永川医院

Primary sponsor:

Yongchuan Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市永川区萱花路439

Primary sponsor's address:

No. 439 Xuanhua Road, Yongchuan District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属永川医院

具体地址:

重庆市永川区萱花路439

Institution
hospital:

Yongchuan Hospital of Chongqing Medical University

Address:

No. 439 Xuanhua Road, Yongchuan District, Chongqing, China

经费或物资来源:

重庆市永川区自然科学基金项目

Source(s) of funding:

Chongqing Yongchuan District Natural Science Foundation Project

研究疾病:

结直肠恶性肿瘤  

Target disease:

Colorectal malignancy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究基于结直肠癌患者围手术期的肠菌紊乱、吸收代谢差、营养不良等临床表现,将口服营养补充剂与肠道微生态制剂相结合。拟在使用肠道微生态制剂调控围手术期患者肠菌平衡的基础上,通过口服高蛋白且比例适当的营养补充剂,提高患者营养物质吸收率、改善患者营养不良的临床状况;进而,提高患者免疫力、减少炎症反应及术后并发症的发生;最终,降低患者术后住院时间、减轻患者经济负担,改善患者生活质量,降低本区域内结直肠癌的死亡率;同时,为术后放化疗等延续性治疗做好基础准备。  

Objectives of Study:

This study is based on clinical manifestations observed in colorectal cancer patients during the perioperative period—such as intestinal microbiota dysbiosis, impaired nutrient absorption and metabolism, and malnutrition—and integrates oral nutritional supplements with intestinal microecological agents. Specifically, it aims to first regulate perioperative intestinal microbiota balance using intestinal microecological agents, and then administer high-protein oral nutritional supplements with an appropriate nutrient composition to enhance nutrient absorption efficiency and ameliorate clinical malnutrition. Consequently, this approach is expected to boost patients’ immune function, reduce inflammatory responses and postoperative complications. Ultimately, it seeks to shorten postoperative hospital stays, alleviate patients’ financial burden, improve quality of life, and lower the regional mortality rate of colorectal cancer. Simultaneously, it lays a foundation for subsequent adjuvant treatments such as radiotherapy and chemotherapy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并其他肠道疾病或免疫系统疾病、严重心血管、呼吸系统疾病和严重代谢性疾病患者;
2.急诊手术者;
3.无法根治性切除手术者;
4.术中出现重大手术意外、抢救后需重症监护患者;
5.术前行放化疗或有使用免疫抑制剂患者;
6.近 1 个月内服用过抗菌药、免疫调节剂、糖皮质激素或肠道益生菌制剂等;
7.对研究用药过敏及其他不能配合完成研究者;

Exclusion criteria:

1.Patients With Other Gastrointestinal Or Immune System Disorders, Severe Cardiovascular Or Respiratory Diseases, And Severe Metabolic Disorders;
2.Patients Requiring Emergency Surgery;
3.Patients For Whom Curative Resection Is Not Possible;
4.Major Intraoperative Surgical Complications Requiring Intensive Care After Resuscitation;
5.Preoperative Chemoradiotherapy Or Use Of Immunosuppressants;
6.Used Antibiotics, Immunomodulators, Glucocorticoids, Or Intestinal Probiotics Within The Past Month.
7.Allergy To The Investigational Drug And Other Conditions That Prevent The Participant From Completing The Study;

研究实施时间:

Study execute time:

From 2023-10-31 00:00:00 To 2025-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-12-15 00:00:00 To 2024-12-13 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Contral Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

试验组

样本量:

30

Group:

Test Group

Sample size:

干预措施:

口服肠道微生态制剂(双歧杆菌四联菌)和营养补充剂

干预措施代码:

Intervention:

Oral Intestinal Microecological Preparation (Quadruple Strain Of Bifidobacterium) And Nutritional Supplements

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属永川医院 

单位级别:

三级甲等 

Institution
hospital:

Yongchuan Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

临床资料分析

指标类型:

次要指标

Outcome:

Clinical Data Analysis

Type:

Secondary indicator

测量时间点:

术后

测量方法:

监测、记录

Measure time point of outcome:

Postoperative

Measure method:

Monitor and Record

指标中文名:

免疫指标

指标类型:

主要指标

Outcome:

Immune Indicators

Type:

Primary indicator

测量时间点:

术前第3天和术后第5天

测量方法:

抽血检验

Measure time point of outcome:

Day 3 before surgery and Day 5 after surgery

Measure method:

Blood Test

指标中文名:

肠道粘膜屏障

指标类型:

次要指标

Outcome:

Intestinal Mucosal Barrier

Type:

Secondary indicator

测量时间点:

术中

测量方法:

病理检查

Measure time point of outcome:

Intraoperative

Measure method:

Pathological Examination

指标中文名:

肠道菌群

指标类型:

次要指标

Outcome:

Gut microbiota

Type:

Secondary indicator

测量时间点:

术前第3天和术后第5天

测量方法:

粪便培养

Measure time point of outcome:

Day 3 Before Surgery And Day 5 After Surgery

Measure method:

Stool Culture

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Quality of Life Score

Type:

Secondary indicator

测量时间点:

术后随访

测量方法:

SF-36量表

Measure time point of outcome:

Postoperative Follow-up

Measure method:

SF-36 Scale

指标中文名:

营养指标

指标类型:

主要指标

Outcome:

Nutritional Information

Type:

Primary indicator

测量时间点:

术前第3天和术后第5天

测量方法:

抽血检验

Measure time point of outcome:

Day 3 Before Surgery And Day 5 After Surgery

Measure method:

Blood test

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肠组织

组织:

Sample Name:

Intestinal Mucosa

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由刘轩君使用计算机产生随机数进行随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization Was Performed By Liu Xuanjun Using A Computer-generated Random Number.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲

Blinding:

Single blind study

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

项目研究结束1年后,将通过网络平台公开。国家生物信息中心 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

One year after the completion of the project study, it will be publicly available on an online platform. China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-12 10:23:01